Immunotherapy in ovarian cancer: we are not there yet
Abstract
With the disappointment brought by modest results of trials testing single-agent immune checkpoint inhibitors in recurrent ovarian cancer, 1 Disis ML Taylor MH Kelly K et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 2019; 5: 393-401 Crossref PubMed Scopus (149) Google Scholar , 2 Varga A Piha-Paul S Ott PA et al. Pembrolizumab in...
Paper Details
Title
Immunotherapy in ovarian cancer: we are not there yet
Published Date
Jul 1, 2021
Journal
Volume
22
Issue
7
Pages
903 - 905
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History